Revvity, Inc.: Leerink Partners raises target price to $180 from $160
RVTY•Leerink Partners raised its target price for Revvity to $180 from $160.
Related News
Upstart Holdings: Piper Sandler cuts target price to $35 from $51
UPST•
Ultragenyx Pharmaceutical: Canaccord Genuity cuts target price to $34 from $39
RARE•
AtriCure target price raised to $67 from $55
ATRC•
Leerink Partners raises Amgen target price to $464 from $395
AMGN•
Crown Holdings cut to neutral from overweight by JPMorgan
CCK•